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Abstract 
  Apoptosis, or programmed cell death, is an evolutionarily conserved developmental 
program that determines cell fate and acts as a defence mechanism, eliminating pathogen-
infected cells and cells that have accumulated undesirable mutations.  Misregulation of 
apoptosis has been implicated in a number of diseases, making knowledge of the mechanisms 
that dictate its execution of great importance to human health.  Cell death is accomplished by 
a family of proteases known as caspases, and has recently been shown to be influenced by 
protein kinase Cδ (PKCδ) through its ability to phosphorylate caspase-3.  
 In order to study the mechanisms of apoptosis, a multidisciplinary approach was 
employed.  First, a simplified mathematical model was created to describe the molecular 
interactions of PKCδ with caspase-3 and expanded to study the mechanisms of the flavonoid 
apigenin in inducing apoptosis.  The model predicts a threshold condition for the activation of 
caspase-3 and also corroborates biological experiments showing caspase-3 activation prior to 
caspase-9.  In addition, our mathematical model predicted that PKCδ reaches a threshold 
apoptotic level in apigenin-induced apoptosis.  These findings were experimentally validated 
using a biological system.  To further investigate the means by which apigenin induces 
apoptosis, we used a microarray of leukemia cells treated with apigenin to identify genes that 
may be transcriptionally regulated by apigenin. We also expanded the investigation into 
caspase-3 phosphorylation by examining the structure of six sites mapped by mass 
spectrometry.  The evolutionary conservation and accessibility of each site was considered.  
Single and multiple site-directed mutagenesis was performed to create phosphomimicking 
mutations at the sites in question.  The enzyme activity of caspase-3 phospho mutants was 
determined using purified proteins.   
Thus, we have investigated means of regulating caspase-3 activity, using PKCδ and 
apigenin as instruments of cell death.  We developed a model of the PKCδ-caspase-3 
relationship and explored the structural constraints involved.  The more that is known about 
the mechanisms by which apoptosis functions and malfunctions, the better we will be able to 
exploit this knowledge to develop new treatments for the array of human diseases caused by 
deregulated apoptosis.  
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Introduction 
Apoptosis is a highly regulated developmental program in which several signalling 
cascades converge to trigger a series of biochemical and morphological changes within a cell, 
leading to its death.  This course of action, when executed at appropriate times, is important 
for not only for development, but also to protect the body from cells that have accumulated 
mutations or been infected by pathogens.  Thus, proper regulation of apoptosis is essential to 
keep the homeostatic cellular balance.  However, when misregulated, apoptosis can 
contribute to disease.  Excessive apoptosis of neurons due to toxic protein aggregates and 
oxidative stress has been implicated in Alzheimer and Parkinson’s diseases, whereas failure 
to execute apoptosis contributes to atherosclerosis, chronic inflammation, and cancer (1, 2, 3, 
4).   
Apoptosis can be activated by several apoptotic cascades that involve the caspases, a 
family of evolutionarily conserved cysteine proteases (Figure 1) (5, 6).  Caspases can be 
classified into initiator and effector caspases based on their role in the apoptotic cascade.  
Initiator caspases, such as caspase-8 and caspase-9, are activated by autocatalytic cleavage in 
response to the instigation of apoptosis.  The activation of the effector caspases, such as 
caspase-3, caspase-6, and caspase-7, is dependent on proteolysis by an initiator caspase (7).  
The extrinsic pathway of apoptosis is initiated when a death domain (DD) containing member 
of the tumor necrosis factor (TNF) receptor superfamily, such as Fas or TRAIL, is activated 
by the binding of a specific extracellular ligand.  The death receptor recruits proteins to form 
the Death Inducing Signalling Complex (DISC), which activates caspase-8 (8).  The intrinsic 
pathway is activated by radiation or by chemotherapeutic drugs.  In this apoptotic pathway, 
changes within the cell result in mitochondrial depolarization and release of cytochrome c 
into the cytoplasm.  Cytochrome c binds to Apaf-1 and these two cofactors enable activation 
of caspase-9 (Figure 1) (7, 9).   
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Figure 1- Simplified model of the apoptotic cascade. 
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caspase-9, respectively (Figure 1) (10, 11).  Caspases-6 and -7, other effector caspases with 
similar structures to that of caspase-3, can also be activated during this cascade (12).  
Caspase-3 is synthesized as an inactive precursor which consists of three domains, the N-
terminal prodomain, the p12 domain, and the C-terminal p17 domain (13).  Once an initiator 
caspase has been activated, it performs the first of two sequential cleavages required to 
activate caspase-3, between the p17 and p12 domains (10).  The second cleavage, between 
the pro and p17 domains, is autocatalytic an enables the formation active caspase-3, a 
tetramer consisting of two p17 and two p12 domains arranged head to tail (Figure 1) (14, 10, 
15).   
Once active, caspase-3 mediates the proteolysis of several proteins with diverse 
biological functions, including, among others, molecules involved in chromatin assembly, 
transcription factors, and modulators of signal transduction pathways (16) (Figure 1).  
Cleavage of caspase-3 substrates causes morphological changes including chromatin 
condensation, nuclear fragmentation, and membrane blebbing which result in the formation 
of an apoptotic body.  Apoptotic bodies prevent damage to surrounding cells by confining the 
contents of the dying cell until it can be phagocytized by a macrophage (7, 10). Activated 
caspase-3 has been shown to participate in positive feedback cleavage of caspase-9, which is 
necessary to fully activate caspase-9 during staurosporine-induced apoptosis in mouse 
embryos and with purified human recombinant proteins in vitro (17, 18) (Figure 1). 
 The molecular pathways regulating apoptosis are increasingly revealed, giving a very 
complex, but still incomplete, picture of how cell fate is determined.  Since the activation of 
caspase-3 is the central step in the execution of apoptosis, a better understanding of its 
regulation will provide the invaluable potential to modulate cell fate at will.  Interestingly, 
while much is known about the regulators of initiator caspases such as caspase-9, or -8, little 
is known about the regulators of caspase-3 (6).  One family of proteins that has a role in 
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regulating apoptosis is the BCL2 family.  BCL2 family proteins play opposing roles in 
apoptosis, with anti-apoptotic members like BCL2 and BCL-XL and pro-apoptotic members 
such as Bax and Bak.  Their role is mostly upstream of caspase-3, by regulating changes in 
the mitochondria, which can lead to apoptosis (19).  Another family, the inhibitor of 
apoptosis proteins (IAP) family, plays a more direct role in caspase regulation.   Members of 
the IAP family, including XIAP, c-IAP1, and c-IAP2, were shown to associate directly with 
the active forms of caspase-3, caspase-7, and caspase-9, inhibiting their activities (9, 20).  All 
IAP proteins contain a baculovirus IAP repeat (BIR) domain, and several also contain a 
RING domain.  The RING domain has E3 ubiquitin ligase activity and XIAP has been shown 
to mediate proteasomal degradation of caspase-3 (9, 21).  XIAP, the most extensively studied 
member of the IAP family, binds caspase-3 and caspase-7 in a manner that covers the active 
site of the protease and prevents substrates from binding.  XIAP binds the small subunit of 
caspase-9 only after the recognition site is revealed by cleavage of caspase-9.  In contrast to 
its binding to caspase-3,  it is unclear whether or not this interaction blocks the active site of 
capsase-9, so the mechanism by which XIAP inhibits caspase-9 is unknown (9).  Notably, 
XIAP can be cleaved by active caspase-3 resulting in the inactivation of its inhibitory 
function (Figure 1) (22).  In contrast to the IAPs, small heat shock protein 27 (Hsp27), 
another protein that is able to regulate caspase-3 by direct binding, binds to the pro domain of 
inactive caspase-3 and prevents the second cleavage that is needed for activation (Figure 1).    
Hsp27 is constitutively expressed in monocytes, but relocalizes to the nucleus during 
spontaneous apoptosis.  Consistent with its role as an inhibitor of caspase-3, it was shown 
that RNA interference against Hsp27 induces apoptosis in monocytes, while overexpression 
of Hsp27 lengthens monocyte life span (23).   
Another recently discovered specific direct regulator of capsase-3 is Protein Kinase 
Cδ (PKCδ) (24).  The PKC family of serine/threonine kinases has many isoforms, some of 
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which are pro-apoptotic, including PKCδ, and others that are anti-apoptotic (25).  PKCδ is 
classified as a novel PKC because its activation can be induced by DAG and PMA, but is 
independent of Ca2+, unlike the conventional PKCs which do respond to Ca2+ and the atypical 
PKCs which respond to neither DAG nor Ca2+ but are activated by phorbol esther.  PKCδ is 
known to phosphorylate a number of substrates including proteins involved in translation, 
such as eukaryotic elongation factor 1-α (eEF-1α) and mTOR, as well as several 
transcription factors, including Sp1, NFκB, and STAT1 (26).  Upon activation, PKCδ 
translocates from the cytoplasm to the plasma membrane.  PKCδ associates with and 
phosphorylates caspase-3, contributing to its apoptotic activity.  During apoptosis, active 
caspase-3 induces the cleavage of PKCδ, causing the catalytic domain of PKCδ to translocate 
to the nucleus where it can phosphorylate a different subset of cellular targets (26, 27) (Figure 
1).  The activation of PKCδ has also been seen during the induction of apoptosis by several 
known anti-cancer agents (28, 29, 30).  Thus, caspase-3 can be regulated at multiple 
checkpoints, creating a safety-lock during the normal cellular life span.  Caspase-3 regulation 
has been demonstrated to occur by a variety of mechanisms and at several different stages 
during the process of activation, adding complexity to the study of caspase-3 regulation.    
The problem of conventional anti-cancer treatments failing due to malignant cells 
acquiring multi-drug resistance has prompted the identification and understanding of 
alternative compounds that induce cell death.  However, while these compounds are being 
identified rapidly, understanding their mechanisms of action is a time consuming process and 
in the majority of cases, remains to be elucidated (7).  Apigenin is a plant polyphenolic 
compound found in fruits and vegetables like parsley, onions, tea, citrus fruits, red wine, and 
chamomile (31, 32), and is emerging as a potential anti-inflammatory, anti-oxidant, and anti-
cancer compound (33, 34, 32, 35, 36).  Using a human leukemia cell line, we recently 
demonstrated that PKCδ and caspase-3 activation mediate apoptosis induced by the flavonoid 
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apigenin (37).  Apigenin inhibits the proliferation of several cancer cells with different 
potency (38, 39, 31).  Notably, we found that apigenin is very effective in inducing apoptosis 
in leukemia cells (37).  However, the mechanism by which apigenin acts is unclear.  Studies 
in prostate or breast cancer have suggested a range of processes that apigenin may effect, 
including estrogen receptor β signalling (40), the NFκB cascade (41), the PI3K/AKT 
dependent ErbB2 pathway (31), the intrinsic pathway of apoptosis (42, 43), and the cell cycle 
(44). 
Interestingly, defective activation of the apoptotic pathway has been found in some 
cancer cells, despite the fact that they express normal levels of caspase-3 and caspase-9 (45).  
These findings suggest the existence of additional mechanisms involved in the activation of 
the caspases that might be impaired in cancer cells, halting the ability of cancer drugs to 
trigger apoptosis.  In this context, the loss of the PKCδ activity, a positive regulator of 
caspase-3, has been reported in breast cancer epithelial cells (46).  Furthermore, decreased 
expression of PKCδ  increased tumor production (47).   
A multidisciplinary approach was taken to aid in understanding the complex 
regulation of caspase-3.  First, a simplified mathematical model was created to describe the 
molecular interactions of PKCδ with caspase-3.  Simulations of caspase-3 and caspase-9 
activities were validated by comparison to biological results obtained with leukemia cells 
treated with etoposide.  The model was expanded to include the drug apigenin, in order to 
elucidate its mechanism of action.  Using this in silico approach, we were able to reproduce 
major features of time-series experiments on PKCδ and caspase-3 activities obtained using 
chemotherapeutic-induced-apoptosis.  Conditions predicted by the model for the promotion 
of apoptosis were then corroborated using a biological system.  Model predictions include the 
requirement of a minimum amount of PKCδ for the induction of caspase-3 activation.  The 
model also vindicates experiments that showed the possibility that under certain 
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circumstances caspase-3 activity prior to caspase-9.  Although this aspect was not discussed, 
data from some groups shows that caspase-3 activity begins to increase before caspase-9 
activity during apoptosis induced by a variety of agents, including apigenin and UV (37, 48).  
Moreover, based on our predictions, we conducted experiments to confirm the minimum 
level of PKCδ activity required to reach an apoptotic threshold in apigenin treated cells.  In 
addition, a microarray approach was used to identify genes in a leukemia cell line that may be 
differentially expressed in response to apigenin treatment. 
The importance of PKCδ in the regulation of caspase-3-dependent apoptosis 
compelled us to investigate the mechanism of caspase-3 phosphorylation.  For this purpose, 
we determined the caspase-3 phosphorylation sites using in silico approaches and mass 
spectrometry and used structural analysis to examine six of these sites in more detail.  The 
structure of four sites was found to be evolutionarily conserved in mammals, and the 
accessibility of each of these sites was assessed.  Single and multiple site-directed 
mutagenesis was performed to create phosphomimicking mutations at the sites in question.  
The ability of the caspase-3 phospho mutants to cleave a specific peptide substrate was 
determined using purified proteins.   
Thus, we have developed a model of the PKCδ-caspase-3 relationship and explored 
the structural constraints involved.  The model predicted that activation of PKCδ is necessary 
for caspase-3 activation in apigenin-induced-apoptosis and that a threshold of apigenin can 
activate PKCδ.  Importantly, we were able to validate this latter result using in vitro kinase 
assays in cells undergoing apoptosis and experiments to identify PKCδ-dependent 
phosphorylation sites are underway.  Understanding the mechanisms that dictate cell death 
will aid in developing treatments for the numerous diseases caused by deregulated apoptosis.  
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Materials and Methods 
The mathematical model 
Construction of the model 
 
The construction of the “Caspase-3 Regulation” model was guided by known 
interactions between the elements of the model found in the literature (Table 2, at end of 
text).  The model contains the intrinsic pathway of apoptosis, with the addition of interactions 
involving PKCδ and a positive feedback loop between caspase-9 and caspase-3 (49).  In 
order to maintain simplicity, the interactions upstream of caspase-9 were condensed into a 
single step referred to as “Upstream Elements” in the model.  In this way, we maintain 
simplicity without ignoring many important interactions in the intrinsic pathway.  Similarly, 
while there are a number of inhibitors of apoptosis proteins, including XIAP, c-IAP1, and c-
IAP2, the combined influence of these proteins is represented in the model simply by “IAP.”  
Ordinary differential equations were used to describe the behaviour of each species in the 
model.  
  The model was translated into computer code and simulated using the software 
Berkeley Madonna version 8.3.9 (R. Macey and G. Oster, University of California at 
Berkeley).  The simulations were carried out using the Runge-Kutta 4 integration method.  
The resulting data were saved in table format, and graphed in Excel for aesthetic purposes.  
For the determination of thresholds and prediction of PKCδ activity, the model was 
altered so that k3a and apigenin, respectively, would be treated as variables, rather than 
parameters.  To do this, these values were removed from the list of parameters and given an 
initial value of 0 and a differential equation in which they increased at a constant rate.  To 
add apigenin to the model, the equation for v3 was altered to include the effect of apigenin on 
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PKCδ activation (See supplementary material 1: Model code for the equations used for each 
version of the model). 
Legitimizing parameters and using the model to make predictions 
In addition to a qualitative comparison of the model with experimental data, the 
values of the parameters used in the simulations were checked against known parameters.  
The literature was searched to find values for the rate constants used in the model, and these 
values are shown in Table 2.  In the model, the parameters are values that have arbitrary units 
with no biological meaning.  To compare parameters with arbitrary units to known values, the 
rate equations were rewritten so that all of the units cancelled out.  The resulting 
dimensionless equations are shown in supplementary material 3: Dimensionless equations.  
These equations contain unit-less parameters that are equal to ratios of rate constants [for 
example: h7 = (k7) / (Km1a*k-7) = (concentration/time) / (concentration/time)].  The unit-less 
parameters are in supplementary material 4: Parameter values, along with the values of their 
ratio in both the simulations and the literature.  The model parameters were altered within an 
acceptable range around the literature values in order to make predictions about the behaviour 
of the system.  
 
Cell culture and reagents 
THP-1 cells were grown at 37°C in a humidified atmosphere of 95% air and 5% CO2 
in media supplemented with 100 U/ml penicillin, and 100 mg/ml streptomycin 
(BioWhittaker, Walkersville, MD).  THP-1 cells were maintained in RPMI 1640 medium 
with L-glutamine (BioWhittaker, Walkersville, MD) supplemented with 5% fetal bovine 
serum (FBS, Hyclone, Logan, UT).  Apigenin, etoposide, and the diluent dimethyl sulfoxide 
(DMSO) were obtained from Sigma-Aldrich (St. Louis, MO).   
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Caspase activity assays 
Lysates from 3 x106 cells were prepared and incubated in a cytobuffer as previously 
described (37).  The activity of caspase-3 was determined using the DEVD-AFC substrate 
and LEHD-AFC was used for caspase-9.  Released AFC were measured using a Cytofluor 
400 fluorimeter (Filters: excitation 400 nm, emission 508 nm; Perspective Co., Framingham, 
MA).   
 
Immunoprecipitation and in vitro kinase assay 
Extract preparation and immunoprecipitation with anti-PKCδ antibodies were carried 
out as previously described (24).  After immunoprecipitation, kinase assays were performed 
by incubating protein A-loaded beads for 1 h at 37°C in the presence of 20 µl kinase assay 
buffer (25 mM Hepes pH 7.3, 10 mM MnCl2, 1 mM MgCl2, 1 mM DTT) containing 5 mCi of 
{γ32P} ATP (Perkin Elmer, Boston, MA), 0.5 mM ATP.  To each reaction, 5 mg of histone 
H2B (Boehringer Mannheim, Roche, Indianapolis, IN) was added as exogenous substrate.  
Reactions were stopped by the addition of 10 ml of 5X Laemmli buffer.  Samples were boiled 
for 5 min and loaded onto a SDS-PAGE.  The kinase activity was measured by 
PhosphorImager.  The same membrane was immunoblotted with anti-PKCδ antibody to 
ensure equal loading of the samples.  
 
The microarray 
RNA isolation and microarray 
THP-1 cells were cultured as above and either left untreated or treated with 50 µM 
apigenin for 3 h.  Total RNA was purified from the cells using RNeasy Mini Kit (Qiagen, 
Valencia, CA).  Hybridization of RNA to an Affymetrix Human Genome U133 Plus 2.0 
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Array (Affymetrix, Santa Clara, CA) was performed by the Functional Genomics Core at The 
Research Institute at Nationwide Children’s Hospital (Columbus, OH). 
 
Data analysis 
Fold change was calculated for each gene, defined as the expression in the apigenin 
treated sample divided by the expression in the non-treated sample.  Normalization, filtering, 
and data analysis was conducting using the software dChip (50).  The data was filtered to find 
genes with a variation across samples of 1<std dev/mean<1000.  Genes involved in biological 
processes of interest were identified in the list of filtered genes by hand and by comparison to 
Kyoto Encylopedia of Genes and Genomes (KEGG) (51, 52, 53) pathways of interest and 
using GenMapp mapps (54).  Functions and roles of genes were investigated first by GO 
((55) accessed May 17, 2007), then in more detail by literature search.  The software 
GenMapp (54) was also used to identify genes of interest and generate images of pathways.       
 
Phosphorylation mutants 
Site-directed mutagenesis and cloning 
Phosphosite mutants were generated with either alanine or aspartic acid in place of the 
wild type amino acid and a His6 tag.  Mutagenesis was conducted using Quick Change Single 
or Multi Site Directed Mutagenesis Kit (Stratagene, Cedar Creek, TX).  Dpn1 treated DNA 
was transformed into E. coli M15 or XL1 Gold cells using the expression vector pQE31.  
Clones were screened by sequencing and analysis of inserts in a 1% agarose gel with 0.5 
µg/mL ethidium bromide.  Plasmid DNA was extracted from overnight cultures of Top10 F 
cells using a QIAprep Spin Miniprep Kit (Qiagen, Valencia, CA, cat.# 27106) and digested 
with SacI and XhoI to yield an insert of approximately 850 bp.       
 
Protein purification 
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Bacteria was grown in Terrific Broth with appropriate antibiotics for selection to an 
OD of approximately A550 0.5.  Protein expression was induced with 1 mM isopropyl 1-thio-
β-D-galactopyranoside (IPTG) for 30 minutes at 20°C.  Bacteria were lysed by sonication in 
sonication buffer (50 mM sodium phosphate, pH 7.8, 300 mM NaCl, 5 mM -mercaptoethanol, 
1% Tween 20, and protease inhibitors (2 µg/ml chymostatin, pepstatin, leupeptin, antipain, 
and 1 mM PMSF)).  Lysates were allowed to bind to Ni2+ beads (Qiagen, Valencia, CA) in the 
presence of RNase (5 µg/ml) for 2 h at 4 °C.  The beads consist of nitrilotriacetic acid (NTA), 
a metal chelator that stably binds Ni2+.  The Ni2+ has two remaining ligand binding sites that 
it uses to bind histidine (Qiagen).  The Ni2+ binds to the tag of 6 consecutive histidines on the 
protein, detaining the recombinant protein but allowing other proteins to flow through the 
column (Figure 2, A).  Tween 20 in the buffer helps to prevent non-specific protein binding 
to the beads.  After binding, the beads were washed with 16 ml of the buffer containing 50 
mM HEPES, pH 7.4, 50 mM NaCl, 10% glycerol, 1% Tween 20, and 1 mM PMSF. The 
protein was eluted with 1-ml aliquots of a step gradient of imidazole dissolved in the wash 
buffer.  The structure of imidazole is the same as the ring on histidine (Figure 2, B and C).  
Therefore, at high concentrations, imidazole competes with histidine for Ni2+ binding and 
causes the recombinant protein to be released from the beads (Qiagen).  Elution fractions 
containing rCaspase-3 were identified by SDS-PAGE.  The protein was dialyzed to dilute the 
imidazole and Tween 20, which could interfere with caspase-3 activity in later assays, and 
put the protein in a buffer that would allow for further chemical analysis.  The dialysis buffer 
consisted of against 50 mM HEPES, pH 7.4, 50 mM NaCl, 10% sucrose, 5 mM DTT, with 1 
L of buffer used for two 1 mL samples.  Dialysis was performed for 6 h, changing to fresh 
buffer after 3 h, at 4°C and proteins were analyzed by Western Blot.     
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Figure 2- Structure of molecules involved in protein purification. 
(A) Structure of His tag on recombinant protein bound to a bead through Ni
2+
-NTA. (B) Structure of 
histidine.  (C) Structure of imidazole. Adapted from Qiagen, The QIAexpressionist, fifth edition. 
 
 
Protein structure 
Phosphorylation sites on caspase-3 were mapped by mass spectrometry.  Potential 
phosphorylation sites were first investigated using the online phospho site prediction tools 
Motif Scan ((56), http://scansite.mit.edu/motifscan_seq.phtml), NetPhos (v. 2.0) and 
NetPhosK (v. 1.0) ((57) http://www.cbs.dtu.dk/services/NetPhos/, (58) 
http://www.cbs.dtu.dk/services/NetPhosK/), and Group-based Phosphorylation Scoring 
Method (GPS) (v. 1.10) ((59, 60) http://bioinformatics.lcd-ustc.org/gps_web/predict.php).  A 
multiple alignment of caspase-3 from a variety of organisms was created using ClustalW and 
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used to asses the evolutionary sequence conservation of each site predicted by the online 
tools.  
Protein structures were predicted using Swiss-Model in first approach mode (61, 62, 
63, 64, 65).  Structures were viewed and analyzed in DeepView Swiss-Pdb Viewer 
(http://www.expasy.org/spdbv/) (64).  PyMolWin was also used to view structures and create 
movies (66). 
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Results  
Development of the ‘Caspase-3 Regulation Model’ 
Caspase-3 activation is very tightly controlled, requiring two sequential cleavages and 
phosphorylation, and sits at the crux of multiple apoptotic pathways, making the mechanism 
of its regulation exceptionally complex.  To gain a better understanding of the regulation of 
apoptosis, we created a model of the intrinsic pathway of apoptosis by synthesizing 
previously published information on biological regulators of cell death and incorporating it 
into a mathematical description.  This type of approach has been used previously to describe 
the biological behaviour of several signalling pathways, such as the NFκB pathway and the 
MAPK pathway (67, 68).  We decided to concentrate on caspase-3 regulation due to its 
crucial role as a converging point for apoptotic signals and as an executioner of cell death and 
we included caspase-9 due to its relevance in chemotherapy-induced-apoptosis.  (Figure 3, A, 
(9)).  Biochemically, the initiator caspase-9 activates caspase-3 by inducing the first cleavage 
of caspase-3, which is followed by a second activating autocatalytic cleavage (Figure 3, B 
and C, (10, 69)).  In turn, caspase-9 activity has been demonstrated to increase due to a 
positive feedback loop mediated by active caspase-3 (Figure 3, D and (17, 18)).  Inactivation 
of both caspase-3 and caspase-9 is mediated at least in part by their ubiquitination by 
inhibitor of apoptosis proteins (IAPs) (Figure 3, E and (20, 21)).  Caspase-3-dependent-
cleavage of the IAPs impairs their inhibitory effect, prompting the execution of cell death 
(Figure 3, F and (22)).  PKCδ, also included in the model, is a recently identified positive 
regulator of caspase-3, promoting its activation (Figure 3, G and (24)).  Caspase-3 has been 
shown to cleave PKCδ, causing the relocalization of the cleaved PKCδ to the nucleus (Figure 
3, H and (27)).  We introduced inactive and cleaved PKCδ in the model as one entity, 
because neither is involved in the activation of caspase-3.   
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Figure 3 - Model of the intrinsic pathway of apoptosis.  
(A) Upstream elements of the intrinsic pathway activate caspase-9.  (B) Caspase-3 is activated by 
caspase-9 cleavage.  (C) An autocatalytic cleavage also contributes to caspase-3 activation.  (D) 
Active caspase-3 is involved in a positive feedback loop that activates caspase-9.  (E) Active 
caspase-3 and active caspases-9 are ubiquitinated by IAP.  (F) Active caspase-3 degrades IAP.  (G) 
Caspase-3 activity is enhanced by phosphorylation by PKCδ.  (H) Active caspase-3 is involved in a 
negative feedback loop with PKCδ.  Caspase-3 cleaves PKCδ, causing it to translocate to the 
nucleus.  (I) To study the effects of apigenin, it was added to some versions of the model (blue).  
Apigenin activates PKCδ.  Solid arrows represent protein changing states by being either synthesized, 
activated, or degraded.  Dashed arrows represent proteins that act as catalysts to promote a reaction. 
The numbers near the arrows are used to identify the rate reactions in (J), i.e. arrow 1 corresponds to 
v1, etc. (J) Rate equations for each reaction in the model, written using Michaelis Menten kinetics.  
(K) ODEs representing the rate of change of the concentration of each protein in the model.  The rate 
of change of concentration is equal to the rate of the protein species being made, minus the rate of it 
being degraded or changed to another state. 
 
Once the qualitative interactions were determined, rate equations were written for 
each step in the model, assuming Michaelis-Menten kinetics for enzymatic steps, Mass 
Action kinetics for drug interactions and degradation, and constant rates of synthesis.  The 
initial amount of each element and the values of the parameters were specified.  Differential 
equations were written to describe the rate of change of the concentration of each element.  
The differential equations are simply equal to the rate of each element being made minus the 
rate of it changing states, i.e. the rate of the arrows in Figure 3 pointing toward the element 
minus the ones pointing away from it.  The rate equations and differential equations of the 
model containing apigenin are given in Table 1 and Figure 1, J and K.  This first version of 
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the model was converted into computer code and named “First Model” (See supplementary 
material 1: Model code). 
 
Validation of the ‘Caspase-3 Regulation Model’ 
Treatment with chemotherapeutic drugs constitutes one of the most common 
approaches to eliminate cancer cells (70, 71).  Etoposide, a topoisomerase inhibitor, is 
commonly used to induce cell death.  We previously reported that PKCδ-dependent 
phosphorylation of caspase-3 is necessary in etoposide-induced apoptosis (24).  We showed 
by in vitro kinase assays that the activity of PKCδ increased during the first hour of etoposide 
treatment, reaching a maximum at around 4 h, and then decreased after 8 h (Figure 4, A and 
(24)).  Caspase-3 activity in the same lysates increased starting at around 3 h and continued to 
increase for the remainder of the time course tested (Figure 4, B and (24)).  We used these 
activation profiles to test whether the model is accurate enough that it fits with previous 
knowledge of the apoptotic pathway.  
To better understand the biological role of PKCδ in caspase-3-dependent apoptosis, 
we used our mathematical model to represent the biological results.  For this purpose, we 
adjusted the arbitrarily chosen parameters of the “First Model” to find parameter values at 
which the output from Berkeley Madonna was qualitatively similar to the experimental 
results (Figure 4, C and (24)).  Using this approach we found that PKCδ is inactive at the 
beginning of the simulation, increases in activity, and then drops back down by hour 5, 
followed by another increase in activity (Figure 4, C, red line).  Caspase-3 was also inactive 
at the beginning of the simulation, and increased until the simulations stop time (Figure 4, C, 
blue line).  The reason for the oscillations in PKCδ activity and the plateau in caspase-3 
activity both beginning at about six and a half hours is unknown but may reflect small 
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maladjustments in the parameters.  Thus, using this model we were able to reproduce the 
qualitative profile of PKCδ and caspase-3 activation during apoptosis.  
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Figure 4 – Model accurately simulates PKCδ and caspase-3 activity in leukemia cells treated 
with 1 µM etoposide. 
(A) Extracts from THP-1 cells cultured for various lengths of time with 1 µM etoposide to induce 
apoptosis were immunoprecipitated (IP) with anti-PKCδ antibodies and subjected to in vitro kinase 
assay using H2B as substrate in the presence of {γ-
32
P} ATP.  The kinase reaction products were 
resolved by SDS-PAGE and transferred to a membrane, and phosphorylated H2B was visualized by 
autoradiography (upper panel).  The same membrane was immunoblotted with anti-PKCδ antibody to 
ensure equal loading of the samples (lower panel).  The kinase activity shown at the top was 
measured by PhosphorImager and normalized by PKCδ density shown at the bottom (24).  (B) 
Caspase-3 activity from the same lysates used in (A) was measured by DEVD-AFC assay (24). (C) 
Model of the activation of PKCδ (red) and caspase-3 (blue) during etoposide-induced apoptosis.  See 
additional file 1: Model code for the code and additional file 2: Simulation parameters for the 
parameters used to perform this analysis.  The model used is ‘First Model’ and the set of parameters 
used in (C) is named ‘validation.’  
 
Caspase-3 activation precedes caspase-9 in apigenin-induced-apoptosis  
In an attempt to identify novel chemotherapeutic approaches we have identified 
apigenin, a plant flavonoid as a potent chemotherapeutic agent for leukemia (37).  Apigenin 
 - 21 - 
induces apoptosis through the intrinsic pathway mediating the activation of caspase-9 and -3.  
Since the complex network of the caspase cascade seems to vary depending on the apoptotic 
stimulus (72), we decided to investigate in more detail the activation of caspase-9 and -3 in 
apigenin-induced-apoptosis.  In light of the fact that the exact mechanism of apigenin has yet 
to be exposed, we anticipated to gain some insight into this chemotherapeutic drug’s line of 
attack using the mathematical model.  Experiments conducted in our laboratory showed that 
cells treated for different times with apigenin showed increased caspase-9 activity at 6 h and 
decreasing activity after 12 h of treatment with apigenin (Figure 5, A and (37)).  In the same 
lysates, we found that caspase-3 activity increased at 3 h, remained similar up to 12 h, and 
decreased after 24 h of apigenin treatment (Figure 5, B and (37)). 
In silico experiments based in the kinetics of caspases during etoposide-induced-
apoptosis were able to adjust well to the data generated in cells.  Due to the successful 
validation of the model in leukemia cells treated with etoposide, we decided to investigate the 
caspase cascade during cell death induced by a different drug.  The caspase cascade can differ 
depending on the apoptotic stimulus and apigenin is a good candidate for study since little is 
known about this relatively new potential chemotherapeutic drug.  Hence, we next used this 
model to study the activation of the caspases during the less characterized system of 
apigenin-induced-apoptosis.  To do this, we simulated the experimental results published by 
Vargo et al, (Figure 5, A and B) using our in silico model (Figure 3).  For this purpose we 
added a term to the rate equation v3 to account for the effects of apigenin (Figure 3, I and 
Table 1, *).  The new model was named “Api-Model” (See supplementary material 1: Model 
code).  Using this model, we showed that caspase-3 activation quickly reaches high levels, 
peaking between 9 and 12 hours, before decreasing quickly (Figure 5, B, blue line).  This is 
exactly the same pattern that was seen by Vargo et al (Figure 5, A, (37)).  Caspase-9 showed 
similar behaviour to caspase-3, but peaked sooner, which is also in agreement with  
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Figure 5 - Model accurately predicts caspase-9 and caspase-3 activity in THP-1 cells in 
response to treatment with apigenin.  
(A) THP-1 cells were treated for various lengths of time with 50 µM apigenin or DMSO (NT) and 
caspase activity was established.  Caspase-9 activity was determined by the LEHD-AFC assay (37).  
(B) Caspase-3 activity was determined by the DEVD-AFC assay. Data represents means ± S.E.M. (N 
= 3) (37).  (C) Model of activation of the activation of caspase-3 (blue) and caspase-9 (green).  (D) 
Enlarged view of the start of caspase activation (Panel 4C) shows that the activity of caspase-3 (blue) 
begins to increase before caspase-9 activity (green).  See additional file 1: Model code for the code 
and additional file 2: Simulation parameters for the parameters used to perform this analysis.  The 
model used is ‘Api-Model’ and the set of parameters used is named ‘validation 2.’ 
 
previously published data (Figure 5, C, green line, A, (37)).  In addition, we found that the 
extent of caspase-9 activity is much lower than caspase-3 activity, as it was in THP-1 cells 
treated with apigenin (data not shown, Figure 5, A and B, note scales on y axis (37)).  
Interestingly, a closer look at the earlier times during addition of apigenin indicated that 
caspase-3 activation preceded the activation of caspase-9 (Figure 5, D).  In a classical 
pathway, caspase-9 is upstream of caspase-3 as part of the intrinsic pathway, so it was 
expected that caspase-9 activity would increase before caspase-3.  These experimental results 
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suggest the presence of a positive feedback loop between caspase-3 and caspase-9 or one of 
its upstream elements.  A feedback loop in which caspase-3 cleaves caspase-9, resulting in 
the amplification of both caspases, has previously been identified as necessary for their full 
activation (14, 17).  For caspase-3 to become active before caspase-9, caspase-3 must be able 
to feedback to activate caspase-9, either directly or indirectly.  
Threshold behaviour of caspase-3 in apigenin-induced-apoptosis 
Based on our findings that caspase-3 activation occurs prior to caspase-9, we studied 
the possibility of the existence of thresholds that can regulate the execution of apoptosis.  For 
this purpose, we determined the relationship of caspase-3 activity and its positive regulator 
PKCδ using our “Caspase-3 Regulation Model.”  The model was altered slightly to make k3a 
into a variable rather than a parameter, and named “Threshold model” (See Methods and 
supplementary material 1: Model code).  In silico experiments using the “Threshold model” 
to postulate the effects of PKCδ on caspase activation revealed that k3a, representing the 
apigenin-dependent rate of activation of PKCδ must reach a threshold in order to activate 
caspase-3 (Figure 6 and Table 1, at end of text).  This simulation also revealed a threshold 
level of PKCδ activation that must be met before caspase-3 activation occurs, and that 
caspase-3 protease activity is all-or-none, with no intermediate phase during which caspase-3 
is partially active under the conditions of the simulation (Figure 6).   
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These findings may help explain the inability of certain cancer cells that normally 
express caspase-9 and -3 to execute cell death (73).  The lack of activation of the apoptotic 
cascade may be due to their lack of the positive action of PKCδ, which may affect the ability 
of caspase-3 activity to reach an apoptotic threshold.  These observations support the use of 
small molecules that promote PKCδ activity as potential targets to promote apoptosis in 
cancer cells (74).  Drugs that target PKCδ may induce apoptosis in cancer cells by aiding the 
cell in reaching the threshold needed to activate caspase-3.   
Prediction of PKCδ activation profile during apigenin-induced-apoptosis 
Apigenin has been shown to induce apoptosis through a mechanism that requires 
PKCδ activation (37).  Since we showed previously that PKCδ positively regulates caspase-3 
activation (24), we used the model to simulate the behaviour of PKCδ activity with different 
concentrations of apigenin.  To do this, the model was altered to make apigenin a variable, 
and named “PKC activity model” (See Methods and supplementary material 1: Model code).  
According to the model, in the absence of apigenin, PKCδ was inactive, but with even a 
small amount of apigenin, PKCδ activity increased dramatically, reaching saturation (Figure 
7, A).  To determine whether the model was able to simulate the biological scenario, we next 
determined the PKCδ activity in apigenin-treated-cells.  For this purpose kinase assays were 
performed using immunoprecipitates of lysates from cells treated with different doses of 
apigenin.  We found a large increase in PKCδ activity in cells treated with amounts of 
apigenin as small as 1 µM (Figure 7, B).  Increasing concentrations of apigenin induced 
sustained PKCδ activity and do not activate PKCδ any further.  Thus, the experimental data 
is consistent with the predictions obtained with our model where PKCδ becomes fully active 
with a very small dose of apigenin, reaching its saturation.  
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The use of plant polyphenols as neutraceuticals in our diet is gaining momentum as a 
better understanding of their mechanisms of action becomes recognized (75)  (76).  Notably, 
our findings showed that a very small amount of apigenin is necessary to activate PKCδ in 
cancer cells.  Additional experiments to clarify the role of apigenin in vivo will further 
elucidate the possibility of utilizing this compound to the benefit of our health.  Our model 
should facilitate the implementation of biological approaches that will provide a faster 
assessment in how apigenin, and likely other related flavonoids, regulate cell death. 
 
Figure 7 - Experiment confirms model prediction of PKCδ activation by apigenin.  
(A) Using the same parameters that validated the model, the activity of PKCδ was simulated at 
various concentrations of apigenin.  See additional file 1: Model code for the code and additional file 
2: Simulation parameters for the parameters used to perform this analysis.  The model used is ‘PKC 
activity model’ and the set of parameters used is named ‘PKC prediction.’  (B) Lysates from THP-1 
cells treated with different concentrations of apigenin were immunoprecipitated with anti-PKCδ 
antibodies and subjected to in vitro kinase assay using H2B as exogenous substrate in the presence 
of {γ-
32
P}ATP.  The kinase reaction products were analyzed by SDS-PAGE and transferred to a 
membrane.  Autoradiography was used to visualize phosphorylated H2B.  The same membrane was 
immunoblotted with anti-PKCδ antibody to ensure equal loading. 
 
Identification of genes regulated by apigenin 
To further elucidate the mechanisms of apigenin-induced-apoptosis, we studied the 
effects of apigenin in gene expression.  There is some evidence that apigenin may modulate 
transcription, since it has been found to effect several transcription factors known to be 
involved in apoptosis, including JUN (77), NFκB (41, 78, 79), and c-MYC (80). Therefore, a 
microarray experiment was conducted to identify genes that exhibit changes in expression 
B A 
0
20
40
60
80
100
120
0.00 0.56 1.11 1.67 2.22 2.78
[Apigenin] (µM)
P
K
C
δδ δδ
 a
c
ti
v
it
y
 (
%
)
Apigenin (µM)  0       1      5     10    25    50 
PKCδ 
P-H2B 
In vitro 
 kinase  
assay 
Immuno- 
blot 
Lane  1      2      3       4      5      6 P
K
C
δδ δδ
 a
c
ti
v
it
y
 (
%
) 120 
100 
80 
60 
40 
20 
0 
0.          .          .         1.7         2.          2.8 
[Api in] (µM) 
 - 26 - 
level during apigenin-induced apoptosis.  For this purpose, THP-1 leukemia cells were 
treated either with apigenin or with DMSO, the diluent of apigenin, for 3 h and mRNA was 
isolated from these samples for hybridization to the microarray.  The data was analyzed using 
the dChip software (50).  After normalization, the data was filtered to remove genes with 
small changes in expression level.  Filtering the original 54,676 probe sets resulted in a list of 
only 1,395 probe sets with large variation across samples that are considered significant.  Of 
these genes, 58% were downregulated, while 42% were upregulated.  A selection of the 
resulting genes with functions relevant to our interests and their fold changes is in Table 3. 
To investigate the functions of the genes that had the largest variation in expression, 
we began by classifying them by their Gene Ontology (GO) terms.  The number of genes 
belonging to each term of the GO Biological Process, Cellular Component, and Molecular 
Function were counted and graphed in Figure 8.  Genes involved in transcription, signal 
transduction, and protein or nucleic acid binding were among those most frequently found in 
our data, some being upregulated and others downregulated (Figure 8).  This may be 
indicative of a large-scale shift in the cell, shutting down some pathways and transcriptional 
programs while turning others on.   
One possible mechanism by which apigenin may cause apoptosis is by mediating 
DNA damage.  Our lab has observed histone release from the nucleus into the cytoplasm 
during apigenin-induced apoptosis, which may be a sign of DNA damage.  HIST1H4A 
(histone cluster 1, H4a), about which very little is known, was seen to be upregulated in our 
data.  NCOA1 (nuclear receptor coactivator 1), a histone acetyltransferase that acts as a 
cofactor to aid transcription by Jun, NFκB and STAT3, was downregulated and could 
potential be involved in the observed histone release, although this is only speculation (81).  
While it is not known if apigenin truly induces DNA damage, if this is the case, it would be 
expected that DNA repair enzymes would be transcriptionally upregulated in response.  
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Indeed, it was found that MSH4 (mutS homolog 4), a gene whose protein product is involved 
in double strand break repair (82), is strongly induced by apigenin, over 11 fold.  In addition, 
two genes TPD52L1 (tumor protein D52-like 1) and CDKN2A (cyclin-dependent kinase 
inhibitor 2A), which have been suggested to play a role in DNA fragmentation during 
apoptosis (83, 84) were upregulated by more than 12 fold.  We also found that BCL2L11 
(BCL2-like 11), a pro-apoptotic member of the BCL2 family that can promote the intrinsic 
pathway, was downregulated by 6.7 fold (Table 3, at end of text) (85).   
Apigenin also has an anti-inflammatory effect, which is not surprising given the links 
between inflammation, apoptosis, and cancer (32, 1, 86, 87).  In addition, JUN and NFκB, 
two transcription factors known to respond to apigenin, have roles in the immune response 
(88, 89).  Therefore, genes involved in inflammation were also investigated for possible 
regulation by apigenin.  The Toll-Like Receptor (TLR) pathway mediates the immune 
response by recognizing a variety of pathogens and malignant cells.  There are at least 12 
TLRs in humans and mice.  When bound to a ligand, these receptors activate the NFκB and 
type I interferon pathways and cause the release of pro-inflammatory cytokines by immune 
cells (90).  It has also been shown that apigenin treatment prevents the release of cytokines in 
response to LPS (79), which is a ligand for TLR4 (90). 
Several genes involved in the TLR pathway were suggested to be downregulated in 
response to apigenin.  The TLR1 receptor is downregulated, as is its downstream effector 
TRAF6 (TNF receptor-associated factor 6), which is an indirect activator of both JUN and 
NFκB, and a direct activator the transcription factor IRF5 (interferon regulatory factor 5) (91, 
92).  JUN and IRF5 themselves are also transcriptionally downregulated.  IRF5 and NFκB 
target several cytokines that are released in response to inflammatory stimulus, including IL-
8 (interleukin 8), MIP-1α (chemokine (C-C motif) ligand 3), and MIP-1β (chemokine (C-C 
motif) ligand 4), which were all downregulated in response to apigenin (93, 94, 95).   This is  
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GO Cellular Component of upregulated genes after filtering
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Figure 8- Genes graphed by Gene Ontology.  
(A) Percentage of upregulated genes belonging to GO Biological Process terms. (B) Percentage of 
downregulated genes belonging to GO Biological Process terms. (C) Percentage of upregulated 
genes belonging to GO Cellular Component terms. (D) Percentage of downregulated genes belonging 
to GO Cellular Component terms. (E) Percentage of upregulated genes belonging to GO Molecular 
Function terms. (F) Percentage of downregulated genes belonging to GO Molecular Function terms. 
Percent of total genes remaining after filtering. 
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consistent with the finding that IL-8 release in response to LPS is inhibited by apigenin in 
human monocytes and mouse macrophages (79).  COX2 (cytochrome c oxidase II), a target 
of NFκB which has been shown to be an oncogene and linked to mutagenesis and reduced 
apoptosis, also shows reduced expression due to apigenin treatment (94, 96) (Table 3, Figure 
9).  These data may give insight into the mechanism of the anti-inflammatory action of 
apigenin.  
In addition to the DNA repair and TLR pathways, several genes identified by microarray to 
be regulated by apigenin are directly involved in the apoptotic cascade.  FAS and CASP8AP2 
(CASP8 associated protein 2), are involved in the extrinsic pathway of apoptosis.  FAS is a 
member of the TNF superfamily of receptors, and acts as a death receptor, recruiting proteins 
to form the DISC, which activates caspase-8 (97).  One of the recruited proteins is 
CASP8AP2, which is also known as FLASH, and may be necessary for caspase-8 activation 
(98).  Imai et al found that CASP8AP2 has a domain similar in sequence to the ATPase 
domain of Apaf-1 and may be a functional analogue of Apaf-1 (98).  This is disputed 
however, as Koonin et al were unable to identify any region of similarity between 
CASP8AP2 and Apaf-1 (99).  IRF1 (interferon regulatory factor 1), a transcription factor that 
induces apoptosis by cleaving caspase-3 in a FADD (and caspase-8 dependent, but death 
ligand independent, manner was also implicated (101) (Table 3, Figure 10).   
Paradoxically, several pro-apoptotic genes were downregulated after apigenin 
treatment, including FAS, BCL2L11, and caspase-3 (Table 3, Figure 10).  This may be 
partially explained by noting that caspase-3 is a target of IRF5, and FAS is a target of NFκB, 
transcription factors that may be directly or indirectly downregulated in these conditions (95, 
94).  Microarrays only measure changes in mRNA expression and it is possible that post-
transcriptional and post-translational regulation may increase the activity of these proteins, 
even if the mRNA encoding them is less abundant.  
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Figure 9- Members of several inflammatory and apoptotic cascades may be transcriptionally 
regulated in response to apigenin treatment. 
Genes from a number of different pathways may be involved in the mechanism of action of apigenin.  
Blue: no change in expression, Green: downregulation, Red: upregulation. References: 1) (51, 53, 52) 
2) (98) 3) (100) 4) (101) 5) (83) 6) (102) 7) (103) 8) (104) 9) (94) 10) (105) 11) (95).  
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Figure 10- Members of several apoptotic cascades may be transcriptionally regulated in 
response to apigenin treatment. 
Genes from a number of different pathways may be involved in the mechanism of action of apigenin.  
Blue: no change in expression, Green: downregulation, Red: upregulation. References: 1) (51, 53, 52) 
2) (98) 3) (83) 4) (23) 5) (101) 6) (82) 7) (84) 8) (85) 9) (106)  
      
While these genes attract interest due to their known roles in apoptosis, the Toll-like 
receptor pathway, and DNA repair, the observed changes in their regulation must be 
confirmed before concrete conclusions can be drawn about their possible involvement in 
apigenin-induced apoptosis.  The genes that have been identified as having particular 
relevance may be further examined using RT-PCR to confirm changes in expression level 
under the conditions tested in the microarray, and western blots of the protein products of 
these genes to tell if changes in expression correlate with changes in protein levels. 
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Molecular characterization of caspase-3 phosphorylation sites 
 Since previous knowledge and the “Caspase-3 Regulation Model” both indicate an 
important role for PKCδ-dependent phosphorylation in the activation of caspase-3 activity, 
we decided to investigate this means of regulation further.  Posttranslational modifications, 
like phosphorylation and proteolysis, are common methods of modulating protein activity.  
Posttranslational modifications are known to be especially critical for members of the caspase 
cascade, many of which are synthesized as inactive precursors to protect the cell against 
accidental apoptosis (13).   
The activity of caspase-3 is regulated by phosphorylation by PKCδ (24). However, to 
date the location and number of phosphorylation sites that are relevant in vivo are unknown.  
Using in silico programs that predict phosphorylation sites, 11 candidate sites were 
suggested, 8 of which were conserved throughout evolution.  Next, mass spectrometry was 
used to map phosphorylation sites on phosphorylated purified caspase-3.  Using this method 
we found seven sites phosphorylated by PKCδ: Ser12, Ser32, Ser36, Ser58, Thr59, Thr67, 
and Thr77.  In silico analysis revealed that all but two, Ser32 and Ser58, of these sites are 
conserved through evolution.  To map the phosphorylation sites and determined their 
biological function, we began the process of generating phosphomutants of caspase-3.  Single 
sites or combinations of sites were mutated to either alanine, to mimic constitutive non-
phosphorylation, or aspartic acid, to mimic constitutive phosphorylation.  This broadly used 
approach has been used to study the phosphorylation of several proteins, including MITF 
(107), Ets1 and Ets2 (108), TRF1 (109), and CHK2 (110).  For a diagram of the experimental 
scheme, see Figure 11. 
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 Mutant caspase-3 was created by site directed mutagenesis and introduced into a 
pQE31 vector in order to add a 6x His tag that would be used later.  This insert was then 
cloned into XL1 Gold and M15 cells.  The DNA from the XL1 Gold cells was sequenced to 
verify that the appropriate mutations were present.  PCR was performed to introduce SacI and 
XhoI sites and the PCR product was ligated into p-ENTR/D-TOPO.  This vector was used for 
the ease and efficiency of ligating a small insert with only one small sticky end using the 
topoisomerase linked to the vector.  The vector was transformed into Top10F cells and 
sequenced again to ensure no unwanted mutations had been introduced.  The plasmid was 
also digested using SacI and XhoI to check for the presence of insert (Figure 12, A).  This 
insert was finally cloned into pDs-red or pCMV, which are mammalian expression vectors.  
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The mutant activity of the caspase-3 proteins will be investigated by determining the percent 
apoptotic cells when treated with an apoptotic stimulus, and comparing to the wild type.   
The DNA that was cloned into M15 cells was used for in vitro analysis.  Expression 
of mutant caspase-3 was induced using IPTG and caspase-3-mutant protein was purified from 
bacteria using a Ni2+-NTA affinity column (see Material and Methods).  Using a 
discontinuous imidazol gradient, we obtained caspase-3 protein at elutions corresponding to 
100 mM imidazol as determined by SDS-PAGE (Figure 12, B, lanes 20 and 21).  
 
Figure 12- Cloning and protein purification.  
(A) Representative gel of caspase-3 insert digested from a d-TOPO vector using SacI and XhoI 
(caspase-3 wt full length, 850 bp) (B) Purification of Asp77 using a Ni2+-NTA affinity column with 
elutions in a discontinuous gradient of imidazole.  Elution fractions containing mutant caspase-3 were 
identified by SDS-PAGE.   
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After dialysis, the activity of the mutant caspase-3 was investigated using a caspase-3 
activity assay.  Caspase-3 was activated by incubation with caspase-9, promoting the first 
cleavage of caspase-3, at 37°C for various time points, up to 2 h.  After activation, a known 
specific substrate of caspase-3, a DEVD peptide, conjugated to the fluorescent molecule 
AFC, was added to the active enzyme.  Caspase-3 cleavage frees AFC, allowing it to 
fluoresce.  The amount of fluorescence was measured to determine the activity of caspase-3.  
It is expected that mutants containing aspartic acid at a phosphorylation site will show faster 
activation, since this negatively charged amino acid mimics phosphorylation, and 
phosphorylation has been shown to increase caspase-3 activity (24).  
 Much more work must be done to definitively map the PKCδ phosphorylation sites of 
caspase-3.  More mutants will be created, and the activities of each mutant protein will be 
tested to determine which sites are important for caspase-3 activity in vitro.  In vitro kinase 
assays will be performed on the alanine mutants, to determine which sites are 
phosphorylated.  Since alanine cannot be phosphorylated, a mutant with an important site 
changed to alanine should show less PKCδ-dependent phosphorylation than the wild type.  
Furthermore, to enable an application to human health, the relevance of these sites to caspase-
3 activation in vivo must also be determined.  This work entails the creation and analysis of 
many mutants and is as yet uncompleted.  
 
Structural characterization of caspase-3 phosphorylation sites 
 In order to narrow down the list of which sites may be phosphorylated by PKCδ in 
vivo, structural analysis was performed on six of these sites, in parallel with the molecular 
studies.  This approach has been extensively used to make predications about protein 
functions and mechanisms based on structural information.  An impediment in our study was 
the lack of available crystal structure for full-length caspase-3.  We based our prediction on 
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the structure of an enzyme composed of the p17 and p12 domains of caspase-3, and lacking 
the amino-terminal pro domain, which has never been crystallized because it is too disordered 
(111).  We are aware of the limitations that this implies but rationalize that structural 
predictions could help to focus our work and help to explain some of our results.  Ser12 is in 
the pro domain of caspase-3, and therefore cannot be studied by this approach.  The 
remaining six sites are found in the p17 domain.  The crystal structure of caspase-3, with the 
locations of the sites of interest, is shown in Figure 13. 
 
 
Figure 13- Structure of caspase-3.  
Structure of the p17 and p12 domains of caspase-3 with the sites under investigation highlighted.  
The missing pro domain would be at the N-terminus, with an unknown structure and position.  Red: 
alpha helix, yellow: beta sheet, gray: loops, green: sites of interest. 
 
Since apoptosis is an evolutionarily conserved mechanism, amino acids that are 
essential to the regulation of caspase-3 are expected to be conserved.  We examined the 
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amino acid alignment of predicted structures of caspase-3 from animals (Figure 14).  
Alignments that take structure into account may differ from sequence alignments because 
sequence alignments allow gaps that are not present in the structure of the protein.  The  
serines at positions 32 and 58 are not conserved in the same location in other mammals, and 
so these sites cannot be phosphorylated by the serine/threonine kinase PKCδ in every 
mammal.  Ser36, Thr59, Thr67, and Thr77 were conserved across mammals, making them 
more likely candidates for phosphorylation by PKCδ.    These four sites were conserved even 
further down the phylogenetic tree:  Ser36 was also conserved in chicken, Thr59 was 
conserved in chicken, zebrafish, and frog, Thr67 was conserved in chicken and fruit fly, and 
Thr77 was conserved in fruit fly (Figure 14).  This same approach was also used to compare 
the structural alignment of the effector caspases -3, -6, and -7, which have similar sequences 
and functions.  Thr59 and Thr67 were conserved in caspase-7, but none of the sites were 
conserved in caspase-6 (Figure 15). 
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Figure 14- Evolutionary conservation of phosphorylation sites. 
 (A) Superimposed images of caspase-3 from mammals. (B) Alignment of caspase-3 of various 
animals from amino acids corresponding to 29 to 78 in human.  This alignment takes structure into 
account, and shows which amino acids are superimposed in (A). red: conserved in mammals, blue: 
not conserved in mammals. 
 (C) Superimposed images of mammalian homologues of caspase-3 with homologues from frog, 
zebrafish, chicken, and fruit fly.    
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Figure 15- Evolutionary conservation of phosphorylation sites in effector caspases. 
 (A) Superimposed images of human caspase-3, caspase-6, and caspase-7. (B) Alignment of effector 
caspases from amino acids corresponding to 29 to 78 in caspase-3.  This alignment takes structure 
into account, and shows which amino acids are superimposed in (A). red: conserved between 
caspase-3 and caspase-7, blue: not conserved. 
 
It is also important to determine whether or not these sites are accessible to a kinase.  
The accessibility of these six sites, as well as Thr130 and Ser150 was addressed.  Thr130 
aligns with Thr125 of caspase-9, which is phosphorylated by ERK in mammalian cell 
extracts, inhibiting caspase-9 activity (112).  Caspase-3 however has not been described as a 
target of ERK.  Ser150 of caspase-3 is known to be phosphorylated by p38, resulting in 
decreased activity and stability of caspase-3 (113).  Caspase-3 is activated by two sequential 
cleavages, the first of which cuts between the p17 and p12 domains.  Therefore, we also 
considered the accessibility of the sites on a structure containing only the p17 domain (Figure 
16, Table 4).  Ser36 and Thr77 became much more accessible with the removal of the p12 
domain.  The accessibilities are shown in Table 4.  Ser150, which is known to be 
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Thr77 when both domains are considered and Thr67 in both cases (Table 4).  These data 
suggest that many of our sites are highly accessible to a kinase and that Ser36, in particular, 
may be an important phosphorylation site, since it is both conserved and highly accessible. 
 
Figure 16- Surface accessibility of amino acids in caspase-3. 
Percent of amino acid surface area that is exposed to the exterior.  A space filling view of the side 
chains is shown.  Blue: accessibility at or above percent given, gray: accessibility below percent 
given. 
 
Table 4 – Percent surface accessibility of amino acids of interest 
Accessibility p17 p12 p17 
< 5%  Thr67 
Thr77 
Thr130 
Thr67 
Thr130 
 
10% - 15% Ser150 Ser150 
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Thr59 
Thr59 
 
p17 p12 
≥ 15% 
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accessible  
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accessible  
p17 
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25% - 30%  Thr77 
45% - 50%  Ser32 
Ser36 
50% - 55% Ser32  
55% - 60% Ser58 Ser58 
 
Surface accessibility of the six potential PKCδ phosphorylation sites and two additional sites, Thr130 
and Ser150, on the p17 and p12 domains of caspase-3 and on the p17 domain alone.  Amino acids 
with increases in accessibility after removal of the p12 domain are highlighted in blue. 
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Discussion and conclusions  
The complex mechanisms by which caspase-3 activity is regulated have been 
investigated using a multidisciplinary approach.  We have built a model of the intrinsic 
pathway of apoptosis that includes the impact of PKCδ and caspase-3 during apoptosis 
induced by chemotherapeutic agents.  Based on these predictions, we determined the 
biological behaviour of PKCδ, a positive regulator of apoptosis, in vivo.  These findings 
showed that we were able to validate our model of apigenin-induced-apoptosis in a biological 
system.  Using this model, we made predictions about how apigenin, a poorly characterized 
plant compound, induces apoptosis.  This model can be expanded for further explorations, 
providing a more rapid approach to assess the potential of new drugs in the regulation of 
apoptosis.   
Interestingly, the model predicted that caspase-3 could become activated before 
caspase-9 during apigenin-induced-apoptosis.  This is curious, since it is widely believed that 
caspase-9 activity is required to activate caspase-3 in the intrinsic pathway, and caspase-8 
activation was not observed in apigenin treated cells (37).  Therefore, it is not clear how 
caspase-3 activation begins in these cells.  In this regard, the presence of the “safety catch” 
regulatory peptide, which keeps the caspase-3 proenzyme inactive, could serve as a 
regulatory region that under certain circumstances could explain the activation of caspase-3 
in the absence of caspase-9 activity (114).  Caspase-3 has also been shown to be activated by 
other caspases, including caspase-11 (115). The oligomerization model also suggests that 
caspase-3 could become active without the aid of any other caspase, if it is present at high 
enough concentrations to bring two molecules close enough for intermolecular autocatalysis 
(10)  
This latter model is complicated by the fact that caspase-3 was shown to be 
transcriptionally downregulated by about 8 fold in response to apigenin.  This observation 
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must be treated with caution because it has not been confirmed by other experiments and may 
be a false result.  Even if true, it is possible that changes in transcription levels do not 
correlate with protein levels in this case.  It has been found in yeast that genes showing even 
a 30 fold change in transcription can maintain a steady state at the protein level (116).  
Indeed, it has been shown that caspase-3 protein levels remain constant throughout apoptosis 
(117, 11).  It seems that caspase-3 is regulated primarily at the post-transcriptional level, 
rather than the transcriptional level. 
One post-transcriptional modification, the phosphorylation of caspase-3 by PKCδ, is 
also being investigated by a variety of approaches, although the work has not been 
completed.  In silico investigation of the protein structure has led to insights into which 
potential PKCδ-dependent phosphorylation sites should be the focus of our first efforts at 
molecular characterization.  Mutagenesis, cloning, protein purification, and assays to measure 
mutant caspase-3 activity are underway.  Phosphorylation by PKCδ is a novel mechanism 
and understanding this level of caspase-3 regulation will greatly add to the basic knowledge 
of apoptosis.  This understanding will translate into improved treatments for the multitude of 
human diseases that have been linked to deregulated apoptosis.    
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Tables 
Table 1 - ODE’s and rate equations describing mathematical model. 
Rate Equation Explanation 
9
9
9
93
1
1
1
1
1
CK
Ck
CK
CCk
v
bm
b
am
aa
+
×
+
+
××
=  
First term: D, Second term: A 
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3
3
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3
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2
2
2
2
2
2
CK
CPKCk
CK
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CK
CCk
v
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ac
bm
ab
am
aa
+
××
+
+
××
+
+
××
=
δ
 
First term: B, Second term: C, 
Third term: G 
δδ PKCkApiPKCkv ba ×+××= 333*  First term: I, absent in model 
without apigenin, Second term: 
other means of activation 
44 kv =  Synthesis 
IAPk
IAPK
IAPCk
v b
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aa ×+
+
××
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−
−
− 4
4
4
4
3
 
First term: F, Second term: other 
means of degradation 
ab
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CK
CIAPk
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3
3
5
5
5
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+
××
= −
−
−
−  
First term: E, Second term: other 
means of degradation 
abm
ab
a
CK
CIAPk
Ckv
9
9
9
6
6
66
+
××
+×=
−
−
−−  
First term: other means of 
degradation, Second term: E 
977 Ckv ×= −−  Degradation 
88 kv =  Synthesis 
388 Ckv ×= −−  Degradation 
Ordinary differential equations Explanation 
( )
( )177
9
vvv
dt
Cd
+−= −  
Synthesis-
(Degradation+Activation) 
( )
61
9
−−= vv
dt
Cd a  
Activation-Degradation 
( )
( )288
3
vvv
dt
Cd
+−= −  
Synthesis-
(Degradation+Activation) 
( )
52
3
−−= vv
dt
Cd a  
Activation-Degradation 
( )
44 −−= vv
dt
IAPd
 
Synthesis-Degradation 
( )
33 −−= vv
dt
PKCd aδ  
Activation-Relocalization 
( )
33 vv
dt
PKCd
−= −
δ
 
Inactive-Activation 
 
 
Subscript numbers refer to numbers near the arrows in Figure 1.  Letters in Explanation column refer 
to letters in Fig. 1.  C3 and C9 stand for casapse-3 and caspase-9, respectively.  Subscript “a” 
denotes active protein. PKCδ stands for both inactive PKCδ and relocalized PKCδ.  *For the version of 
the model that lacks apigenin, δPKCkv b ×= 33 . 
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Table 2 – Literature values for rate constants 
Parameter Rate Constant Reference 
ak1  3.57 x 10
-3 s-1 (118) (converted to s-1) 
amK 1  5.56 nM
 (118) (converted to s-1) 
bk1  ---  
bmK 1  ---  
ak2  1.01 min
-1 (118) 
amK 2  1.39 x 10
-7 M (119) 
bk2  3.57 x 10
-3 s-1 (118) (assumed same as k1a, converted to s
-1) 
bmK 2  5.56 nM
 (118) (assumed same as Km1a, converted to s
-1) 
ck2  ---  
cmK 2  ---  
ak3  ---  
bk3  ---  
ak 3−  3.57 x 10
-3 s-1 (118) (assumed same as k1a, converted to s
-1) 
amK 3−  5.56 nM
 (118) (assumed same as Km1a, converted to s
-1) 
bk 3−  8.02 x 10
-6 s-1 (120) (converted to s-1) 
4k  0.04 nM s
-1 (49) 
ak 4−  3.57 x 10
-3 s-1 (118) (assumed same as k1a, converted to s
-1) 
amK 4−  5.56 nM
 (118) (assumed same as Km1a, converted to s
-1) 
bk 4−  6 x 10
-3 s-1 (121) 
ak 5−  1 x 10
-3 (49) 
amK 5−  ---  
bk 5−  1 x 10
-3 s-1 (49) 
ak 6−  1 x 10
-3 s-1 (49) 
bk 6−  1 x 10
-3 (49) 
bmK 6−  ---  
7k  0.02 nM s
-1 (49) 
7−k  1 x 10
-3 s-1 (49) 
8k  0.2 nM s
-1 (49) 
8−k  3.5 x 10
-5 s-1  (122) (calculated from half life) 
Api  0-50 µM Used in experiments 
 
Literature values of rate constants with references. 
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Table 3 – Microarray results of interest 
Gene Probe Set 
Fold 
Change 
About References 
HIST1H4A 208046_at 7.33407   
FAS 
(CD95) 
215719_x_at 0.100296 
TNF family of receptors. Induces 
apoptosis. 
(97) 
 216252_x_at 0.152671   
CASP8AP
2 (FLASH) 
1570001_at 35.94334 
Structure of Cajal bodies. May be needed 
to activate caspase-8. Inhibits signalling 
of glucocorticoid receptor. 
(123, 98, 124) 
CASP4 213596_at 0.143098 
Inflammatory caspase. Interacts with 
TRAF6. Leads to NFκB activation and 
cytokine secretion. 
(100) 
IRF6 1552478_a_at 15.47631 
Transcription factor. Van der Woude 
Syndrome (developmental disorder 
characterized by cleft lip/palate). 
(125) 
BCL2L11 
(BIM) 
1555372_at 0.149572 
Downregulated in prostate cancer.  
Expression is inhibited by NFκB. 
(41, 126) 
JUN (AP1) 201466_s_at 0.105048 
Transcription factor. Phosphorylated by 
JNK. Required for progression thru G1. 
Regulated by growth factors, cytokines, 
oxidative stress, and UV. Proliferative and 
anti-apoptotic functions. Apigenin 
decreases levels of JUN. 
(88, 77) 
IRF1 202531_at 0.170219 
Transcription factor. Induces apoptosis. 
Required for the action of several 
chemotherapeutic drugs. 
(101) 
TNFSF10 
(TRAIL) 
202688_at 0.107112 
Required for apoptosis in inactive CD8+ 
cells. 
(127) 
 202687_s_at 0.138739   
IRF5 205468_s_at 0.162689 
Type I interferon and TLR pathways. 
Systemic lupus erythematosus, 
rheumatoid arthritis, inflammatory bowel 
disease, and MS. Innate immunity. 
Required for DNA damage induced 
apoptosis and tumor suppression. 
(128, 129) 
TRAF5 204352_at 0.103122 
CD40 signalling. NFκB activation. B and T 
cell signalling, organogenesis, cell 
survival. Mediates NFκB, MAPK, and JNK 
pathways. 
(130, 102) 
TRAF4 202871_at 0.161888 
Expressed in undifferentiated cells. Low 
TRAF4 expression correlates to more 
invasive breast cancer. 
(91, 131) 
TPD52L1 
(D53) 
203786_s_at 15.12698 
None detected in children diagnosed with 
ALL or AML. Upregulated during G2/M 
transition MAPKKK that activates JNK 
and p38 cascades. Calcium signalling. 
(132, 133, 83) 
CASP3 236729_at 0.124807 
Effector caspase. Activated by the initiator 
caspases, including caspase-8 and 
caspase-9. Protease.   
 
(10, 11, 16).   
CASP5 207500_at 11.17689 
Inflammatory caspase. Activated by the 
NALP1 inflammasome. Causes cytokine 
release through NFκB. Apoptosis. 
(103, 134) 
IRAK2 1553739_at 10.93345 
Activation of NFκB. IL-1R and TLR4 
signalling. May be involved in 
(104, 135) 
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carcinogenesis. 
PTGS2 
(COX2) 
204748_at 0.154179 
Linked to mutagenesis, mitogenesis, 
angiogenesis, reduced apoptosis, 
metastasis, and immunosuppression 
(96) 
IL8 202859_x_at 0.139883 
Target of IRF5. Target of NFκB. Apigenin 
treated monocytes and mouse 
macrophages have reduced production of 
IL8.  
 
(51, 52, 53, 
79, 94) 
TRAF6 205558_at 0.069604 
IL1 and IL18 signalling. Activates JNK 
and NFκB. Interacts with IRAK.  
(91)   
TLR1 210176_at 0.152558 
Response to invading pathogens. MyD88-
dependent signalling for release of 
cytokines.  
(136, 90) 
 239021_at 0.154856   
RIPK1 
(RIP1) 
226551_at 0.054569 
Needed for casp8 activation. Apoptosis. 
Activation of NFκB and JNK. 
Serine/threonine kinase.  
(105) 
CCL3 
(MIP-1α) 
205114_s_at 0.070623 
Target of IRF5. Ligand of CCR1 and 
CCR5 receptors. Chemokine. Induced by 
LPS, IL-1β, IFN-γ.  
(51, 52, 53, 
137, 138) 
CCL4 
(MIP-1β) 
234616_at 0.133971 
Target of IRF5. Chemokine. Induced by 
LPS or IL-7.  
 
(51, 52, 53, 
138)  
MSH4 210533_at 11.18889 
Meitotic and mitotic DNA double strand 
break repair and DNA damage response. 
Required for meiosis. Complexes with 
MSH5. ATP catalysis. Resolving Holliday 
junctions. No shown role in mismatch 
repair  
(82) 
HMOX1 203665_at 0.028441 
Converts heme into bile pigments. Source 
of carbon monoxide, which is involved in 
inflammation, proliferation, apoptosis. 
Induced by stress, ROS, LPS, IL-1α IL-
1β, IL-6, IL-11, TNFα.  
(139) 
BTG2 201235_s_at 0.118314 
Tumor suppressor. Induced by p53-
dependent mechanism and may be 
involved in cell cycle control and response 
to DNA damage. Directly or indirectly 
regulates transcription of cyclin D1.  
(140, 106, 
141) 
ESCO2 241252_at 0.037344 
Acetyltransferase. Required for sister 
chromatid cohesion during S phase. 
Roberts Syndrome (craniofacial defects, 
loss of cohesion at centromere and Y 
chromosome).  
(142) 
 
Selected genes with a significant fold change. 
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METHOD RK4 
STARTTIME = 0 
STOPTIME = 100 
DT = 0.01 
 
{differential equations} 
 
d/dt(C9) = v7-(vm7+v1) 
d/dt(C9a) = v1-vm6 
d/dt(C3) = v8-(vm8+v2) 
d/dt(C3a) = v2-vm5 
d/dt(IAP) = v4-vm4 
d/dt(PKCa) = v3-vm3 
d/dt(PKCi) = vm3-v3 
 
v1 = k1a*C3a*C9/(KKm1a+C9) + k1b*C9/(KKm1b+C9) 
v2 = k2a*C9a*C3/(KKm2a+C3) 
       + k2b*C3a*C3/(KKm2b+C3)  
       + k2c*PKCa*C3/(KKm2c+C3) 
v3 = k3b*PKCi 
vm3 = km3a*C3a*PKCa/(KKm3a+PKCa) + km3b*PKCa 
v4 = k4 
vm4 = km4a*C3a*IAP/(KKm4a+IAP)+km4b*IAP 
vm5 = km5a*IAP*C3a/(KKm5a+C3a)+km5b*C3a 
vm6 = km6a*C9a + km6b*IAP*C9a/(KKm6b+C9a) 
v7 = k7 
vm7 = km7*C9 
v8 = k8 
vm8 = km8*C3 
 
init C9 = 0 
init C9a = 0.001 
init C3 = 1.0 
init C3a = 0.001 
init IAP = 0.1 
init PKCa = 0.01 
init PKCi = 0.07 
 
k1a = 0.1 
KKm1a =0.01 
k1b = 0.1 
KKm1b = 0.001 
k2a = 0.4 
KKm2a=0.01 
k2b = 0.4 
KKm2b=0.01 
k2c = 0.4 
KKm2c=0.01 
k3b = 0.2 
km3a = 10 
KKm3a =0.01 
km3b = 1.0 
k4 = 0.5 
km4a = 0.1 
KKm4a = 0.01 
km4b = 1.5 
km5a = 0.16 
KKm5a=0.01 
km5b= 0.16 
km6a = 0.3 
km6b = 1 
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KKm6b = 0.001 
k7 = 0.5 
km7 = 0.1 
k8 = 0.08 
km8 = 0.08 
{End} 
 
 
{Api-Model} 
 
METHOD RK4 
STARTTIME = 0 
STOPTIME = 100 
DT = 0.01 
 
{differential equations} 
 
d/dt(C9) = v7-(vm7+v1) 
d/dt(C9a) = v1-vm6 
d/dt(C3) = v8-(vm8+v2) 
d/dt(C3a) = v2-vm5 
d/dt(IAP) = v4-vm4 
d/dt(PKCa) = v3-vm3 
d/dt(PKCi) = vm3-v3 
 
v1 = k1a*C3a*C9/(KKm1a+C9) + k1b*C9/(KKm1b+C9) 
v2 = k2a*C9a*C3/(KKm2a+C3) 
       + k2b*C3a*C3/(KKm2b+C3)  
       + k2c*PKCa*C3/(KKm2c+C3) 
v3 = k3a*PKCi*Api+(k3b*PKCi) 
vm3 = km3a*C3a*PKCa/(KKm3a+PKCa) + km3b*PKCa 
v4 = k4 
vm4 = km4a*C3a*IAP/(KKm4a+IAP)+km4b*IAP 
vm5 = km5a*IAP*C3a/(KKm5a+C3a)+km5b*C3a 
vm6 = km6a*C9a + km6b*IAP*C9a/(KKm6b+C9a) 
v7 = k7 
vm7 = km7*C9 
v8 = k8 
vm8 = km8*C3 
 
init C9 = 0 
init C9a = 0.001 
init C3 = 1.0 
init C3a = 0.001 
init IAP = 0.1 
init PKCa = 0.01 
init PKCi = 0.07 
 
k1a = 0.1 
KKm1a =0.01 
k1b = 0.14 
KKm1b = 0.001 
k2a = 2 
KKm2a=0.001 
k2b = 0.34 
KKm2b=0.001 
k2c = 5 
KKm2c=0.001 
k3a = 0.8 
k3b = 0.2 
km3a = 10 
 - 53 - 
KKm3a =0.01 
km3b = 1.0 
k4 = 0.39 
km4a = 0.1 
KKm4a = 0.01 
km4b = 0.7 
km5a = 1.57 
KKm5a=0.001 
km5b= 5 
km6a = 0.3 
km6b = 1 
KKm6b = 0.001 
k7 = 0.16 
km7 = 0.05 
k8 = 0.08 
km8 = 0.08 
Api = 50 
{End} 
 
 
{Threshold model} 
 
METHOD RK4 
STARTTIME = 0 
STOPTIME = 100 
DT = 0.01 
 
{differential equations} 
 
d/dt(C9) = v7-(vm7+v1) 
d/dt(C9a) = v1-vm6 
d/dt(C3) = v8-(vm8+v2) 
d/dt(C3a) = v2-vm5 
d/dt(IAP) = v4-vm4 
d/dt(PKCa) = v3-vm3 
d/dt(PKCi) = vm3-v3 
d/dt(k3a) = 0.00001 
 
v1 = k1a*C3a*C9/(KKm1a+C9) + k1b*C9/(KKm1b+C9) 
v2 = k2a*C9a*C3/(KKm2a+C3) 
       + k2b*C3a*C3/(KKm2b+C3)  
       + k2c*PKCa*C3/(KKm2c+C3) 
v3 = k3a*PKCi*Api+k3b*PKCi 
vm3 = km3a*C3a*PKCa/(KKm3a+PKCa) + km3b*PKCa 
v4 = k4 
vm4 = km4a*C3a*IAP/(KKm4a+IAP)+km4b*IAP 
vm5 = km5a*IAP*C3a/(KKm5a+C3a)+km5b*C3a 
vm6 = km6a*C9a + km6b*IAP*C9a/(KKm6b+C9a) 
v7 = k7 
vm7 = km7*C9 
v8 = k8 
vm8 = km8*C3 
 
init C9 = 0 
init C9a = 0.001 
init C3 = 1.0 
init C3a = 0.001 
init IAP = 0.1 
init PKCa = 0.01 
init PKCi = 0.07 
init k3a = 0 
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k1a = 1.0 
KKm1a =0.01 
k1b = 0.1 
KKm1b = 0.001 
k2a = 0.4 
KKm2a=0.01 
k2b = 0.4 
KKm2b=0.01 
k2c = 0.4 
KKm2c=0.01 
k3b = 0.2 
km3a = 10 
KKm3a =0.01 
km3b = 1.0 
k4 = 0.5 
km4a = 0.1 
KKm4a = 0.01 
km4b = 1.5 
km5a = 0.16 
KKm5a=0.01 
km5b= 0.16 
km6a = 0.3 
km6b = 1 
KKm6b = 0.001 
k7 = 0.5 
km7 = 0.1 
k8 = 0.08 
km8 = 0.08 
Api = 50 
{End} 
 
 
{PKC activity model} 
 
METHOD RK4 
STARTTIME = 0 
STOPTIME = 100 
DT = 0.01 
 
{differential equations} 
 
d/dt(C9) = v7-(vm7+v1) 
d/dt(C9a) = v1-vm6 
d/dt(C3) = v8-(vm8+v2) 
d/dt(C3a) = v2-vm5 
d/dt(IAP) = v4-vm4 
d/dt(PKCa) = v3-vm3 
d/dt(PKCi) = vm3-v3 
d/dt(Api) = 0.00001 
 
v1 = k1a*C3a*C9/(KKm1a+C9) + k1b*C9/(KKm1b+C9) 
v2 = k2a*C9a*C3/(KKm2a+C3) 
       + k2b*C3a*C3/(KKm2b+C3)  
       + k2c*PKCa*C3/(KKm2c+C3) 
v3 = k3a*PKCi*Api+(k3b*PKCi) 
vm3 = km3a*C3a*PKCa/(KKm3a+PKCa) + km3b*PKCa 
v4 = k4 
vm4 = km4a*C3a*IAP/(KKm4a+IAP)+km4b*IAP 
vm5 = km5a*IAP*C3a/(KKm5a+C3a)+km5b*C3a 
vm6 = km6a*C9a + km6b*IAP*C9a/(KKm6b+C9a) 
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v7 = k7 
vm7 = km7*C9 
v8 = k8 
vm8 = km8*C3 
 
init C9 = 0 
init C9a = 0.001 
init C3 = 1.0 
init C3a = 0.001 
init IAP = 0.1 
init PKCa = 0.01 
init PKCi = 0.07 
init Api = 0 
 
k1a = 0.1 
KKm1a=0.01 
k1b = 0.14 
KKm1b = 0.001 
k2a = 2 
KKm2a=0.001 
k2b = 0.34 
KKm2b=0.001 
k2c = 5 
KKm2c=0.001 
k3a = 0.8 
k3b = 0.2 
km3a = 10 
KKm3a=0.01 
km3b = 1.0 
k4 = 0.39 
km4a = 0.1 
KKm4a = 0.01 
km4b = 0.7 
km5a = 1.57 
KKm5a=0.001 
km5b= 5 
km6a = 0.3 
km6b = 1 
KKm6b = 0.001 
k7 = 0.16 
km7 = 0.05 
k8 = 0.08 
km8 = 0.08 
{End}  
 
Code for the models used in Berkeley Madonna. 
 
Supplementary material 2 – Simulation parameters 
parameter First Model validation oscillation Api-Model validation 2 
            
stoptime 100 1.6 40 100 0.16 
k1a 0.1 0.1 0.07 0.1 0.1 
KKm1a 0.01 0.01 0.01 0.01 0.01 
k1b 0.1 0.1 0.05 0.14 0.1 
KKm1b 0.001 0.001 0.001 0.001 0.0042 
k2a 0.4 3.17 0.01 2 1 
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KKm2a 0.01 0.01 0.01 0.001 0.001 
k2b 0.4 2.44 0.75 0.34 0.68 
KKm2b 0.01 0.01 0.01 0.001 0.001 
k2c 0.4 0.3 1 5 7.1 
KKm2c 0.01 0.01 0.01 0.001 0.001 
k3a N/A N/A N/A 0.8 0.8 
k3b 0.2 1 0.38 0.2 0.2 
km3a 10 3.7 0.92 10 10 
KKm3a 0.01 0.01 0.01 0.01 0.01 
km3b 1 0.1 0.001 1 1 
k4 0.5 0.07 0.5 0.39 1 
km4a 0.1 0.1 0.01 0.1 0.01 
KKm4a 0.01 0.01 0.01 0.01 0.01 
km4b 1.5 0.1 1.5 0.7 0.01 
km5a 0.16 0.01 0.16 1.57 4.1 
KKm5a 0.01 0.01 0.01 0.001 0.001 
km5b 0.16 0.01 0.15 5 10 
km6a 0.3 0.01 0.92 0.3 2 
km6b 1 0.01 0.001 1 2.1 
KKm6b 0.001 0.001 0.001 0.001 0.001 
k7 0.5 0.5 0.5 0.16 0.4 
km7 0.1 0.1 0.1 0.05 0.001 
k8 0.08 0.001 0.08 0.08 0.08 
km8 0.08 0.01 0.08 0.08 0.08 
Api N/A N/A N/A 50 50 
init PKCa 0.01 0.001 0.001 0.01 0.01 
init C9a 0.001 0.001 0.001 0.001 2.00E-04 
init C3a 0.001 0.001 0.001 0.001 2.00E-04 
 
Supplementary material 2- Simulation parameters - Continued 
parameter Threshold model threshold 
PKC activity 
model pkc prediction 
         
stoptime 100 200 100 25 
k1a 1 1 0.1 0.1 
KKm1a 0.01 0.01 0.01 0.01 
k1b 0.1 0.02 0.14 0.28 
KKm1b 0.001 0.001 0.001 0.001 
k2a 0.4 0.45 2 2.335 
KKm2a 0.01 0.01 0.001 0.001 
k2b 0.4 0.4 0.34 0.399 
KKm2b 0.01 0.01 0.001 0.001 
k2c 0.4 0.02 5 1.38 
KKm2c 0.01 0.01 0.001 0.001 
k3a N/A N/A 0.8 0.8 
k3b 0.2 0.2 0.2 0.091 
km3a 10 10 10 10 
KKm3a 0.01 0.01 0.01 0.01 
km3b 1 1 1 1 
k4 0.5 0.5 0.39 0.39 
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km4a 0.1 0.1 0.1 0.1 
KKm4a 0.01 0.01 0.01 0.01 
km4b 1.5 1.5 0.7 0.7 
km5a 0.16 0.16 1.57 1.57 
KKm5a 0.01 0.01 0.001 0.001 
km5b 0.16 0.16 5 5 
km6a 0.3 0.3 0.3 0.3 
km6b 1 0.04 1 0.23 
KKm6b 0.001 0.001 0.001 0.001 
k7 0.5 0.5 0.16 0.16 
km7 0.1 0.1 0.05 0.05 
k8 0.08 0.16 0.08 0.08 
km8 0.08 0.175 0.08 0.08 
Api 50 50 N/A N/A 
init PKCa 0.01 0.01 0.01 0.01 
init C9a 0.001 0.001 0.001 0.001 
init C3a 0.001 0.001 0.001 0.001 
 
The parameters used for each validation and simulation. 
 
Supplementary material 3 – Dimensionless equations 
Dimensionless Equations 
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Supplementary material 3 – Dimensionless equations - Continued 
Dimensionless Concentrations Dimensionless Parameters 
 
amK
C
1
9
]9[
=ξ  
 
[ ]
am
a
a
K
C
1
9
9
=ξ  
 
amK
C
2
3
]3[
=ξ  
 
[ ]
am
a
a
K
C
2
3
3
=ξ  
 
[ ]
am
a
a
K
C
1
13
3
=ξ  
 
am
a
p
K
PKC
3
][
−
=ξ  
 
[ ]
am
i
pi
K
PKC
3−
=ξ  
 
[ ]
am
total
ptot
K
PKC
3−
=ξ  
 
 
][
4am
iap
K
IAP
−
=ξ  
 
 
7
1
1
17
7
7    ,  
−−
==
k
k
h
Kk
k
h a
am
 
 
am
b
b
Kk
k
h
17
1
1
−
=   ,  
am
bm
m
K
K
p
1
1
1 =  ,  
am
bm
m
K
K
p
1
6
6
−=  
 
ama
b
B
a
a
A
Kk
k
h
k
k
h
16
1
6
1    ,  
−−
==   ,  
ama
amb
C
Kk
Kk
h
16
46
−
−−=  
 
am
ama
a
am Kk
Kk
p
Kk
k
h
28
12
2
28
8
8    ,  
−−
==  
 
8
2
2
−
=
k
k
p bb   ,  
am
amc
c
Kk
Kk
p
28
32
2
−
−=  
 
am
bm
bm
K
K
p
2
2
2 =   ,  
am
cm
cm
K
K
p
2
2
2 =  
 
amb
ama
a
Kk
Kk
a
25
12
2
−
=   ,  
b
b
b
k
k
a
5
2
2
−
=   ,  
amb
amc
c
Kk
Kk
a
25
32
2
−
−=  
 
amb
ama
Kk
Kk
a
25
45
5
−
−−=   ,  
am
am
m
K
K
p
2
5
5
−=  
 
amb
ama
m
amb Kk
Kk
p
Kk
k
h
44
24
4
44
4
4   ,  
−−
−
−−
==  
 
amb
ama
m
b
ba
Kk
Kk
p
k
kApik
h
33
23
3
3
33
3    ,   
)][(
−−
−
−
=
+
=  
 
 
Equations of the model, rewritten to be dimensionless, the dimensionless concentrations, and 
dimensionless parameters. 
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Supplementary material 4 – Parameter values 
Dimensionless 
parameter 
Highest value used in 
simulation 
Lowest value used in 
simulation 
Literature value 
7h  50000 160 0.359712 
1h  1000 0.7 3.566667 
bh1  28000 20 0.06295 
1mp  0.42 0.1 --- 
Ah  100 0.035 3.566667 
Bh  2800 1 --- 
Ch  210 0.005 1.00E+00 
8h  16000 0.571429 41.10997 
ap2  3170 0.057143 192.381 
bp2  244 2.28 101.9048 
cp2  7100 0.114286 --- 
bmp 2  10 0.1 0.4 
cmp 2  10 0.1 --- 
6mp  0.1 0.1 --- 
aa2  3170 0.001 6.733333 
ba2  244 0.0399 3.566667 
ca2  7100 0.002 --- 
5a  4100 0.001 0.4 
5mp  10 0.1 --- 
4h  10000 4.666667 1.20E-01 
4mp  10 0.000667 1.486111 
3h  41000 0.091 --- 
3mp  10000 0.092 1111.454 
 
The values of the model’s parameters were converted into corresponding dimensionless parameters.  
Comparison of the range of dimensionless parameters used in the simulations to the values of the 
dimensionless parameters based on the literature. 
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